Почетна › Карцином на јајниците › Пенсилванија
Клинички испитувања за Карцином на јајниците во Пенсилванија
69 студии за Карцином на јајниците бараат учесници на локации во Пенсилванија.
Градови во Пенсилванија
Официјален текст на студијата (англиски)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- и уште 18
Се регрутираФаза 2
Сите возрасти · Сите полови · Ажурирано 2.10.2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- IRMC Cancer Center, Indiana
- UPMC Hillman Cancer Center - New Castle, New Castle
- и уште 2
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07059884A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Се регрутираФаза 1
Возраст 19 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06586957A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05877599A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0232 - University of Pennsylvania, Philadelphia
- Site 0178 - Thomas Jefferson University, Philadelphia
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 29.9.2026 · NCT05128825Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- University of Pennsylvania, Philadelphia
Се регрутира
Возраст 18 и постари · Жени · Ажурирано 29.9.2026 · NCT05287451A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- St. Lukes University Hospital /ID# 274362, Bethlehem
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612, Philadelphia
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 29.9.2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT05867251DESTINY-PANTUMOUR04
- Research Site, Philadelphia
Се регрутираНабљудувачка студија
Возраст од 18 до 130 · Сите полови · Ажурирано 25.9.2026 · NCT07124000A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Се регрутираФаза 1/2
Возраст 18 и постари · Жени · Ажурирано 24.9.2026 · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06128551A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Penn Medicine University of Pennsylvania Health System /ID# 277963, Philadelphia
- Western Pennsylvania Gynecologic Oncology /ID# 278632, Pittsburgh
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 22.9.2026 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Pennsylvania Hospital, Philadelphia
- Jefferson Health Honickman Center, Philadelphia
- Asplundh Cancer Pavilion, Willow Grove
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213791Prehabilitation in High-risk Oncologic Surgery
- Fox Chase Cancer Center - Philadelphia, Philadelphia
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07638410BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- University of Pennsylvania, Philadelphia
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT04752826A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Hospital of the University of Pennsylvania ( Site 0071), Philadelphia
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 17.9.2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Penn State College of Medicine, Hershey
Се регрутираФаза 2
Возраст од 18 до 99 · Жени · Ажурирано 15.9.2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
- Allegheny Health Network- West Penn Hospital, Pittsburgh
- Lankenau Medical Center, Wynnewood
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 15.9.2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Allegheny Singer, Pittsburgh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06303505Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- St. Luke's University Health Network, Bethlehem
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 14.9.2026 · NCT04575935Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh
- West Penn Hospital of Allegheny Health Network, Pittsburgh
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 14.9.2026 · NCT06787612ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT05059444A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT05123482A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 3.9.2026 · NCT06824467FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.9.2026 · NCT07216105Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- AHN West Penn Hospital, Pittsburgh
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 26.8.2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
Се регрутираФаза 1
Возраст 15 и постари · Сите полови · Ажурирано 25.8.2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Се регрутираФаза 1/2
12 Months – 30 Years · Сите полови · Ажурирано 25.8.2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 21.8.2026 · NCT06774963Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT07001748A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- SCRI - Sydney Kimmel Cancer Center - Jefferson Health, Philadelphia
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07470853The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
- ACPMP, Springfield
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 17.8.2026 · NCT07769346A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0109, Philadelphia
- Site 0113, Philadelphia
- Site 0114, Willow Grove
Се регрутираФаза 3
Возраст 18 и постари · Жени · Ажурирано 12.8.2026 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Jefferson Abington Hospital, Abington
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Penn State Milton S Hershey Medical Center, Hershey
- и уште 15
Се регрутира
Возраст од 35 до 50 · Жени · Ажурирано 7.8.2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Saint Luke's Cancer Center - Allentown, Allentown
- Saint Luke's University Hospital-Bethlehem Campus, Bethlehem
- и уште 21
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 7.8.2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.7.2026 · NCT04657068Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.